全基因组无创产前检测(NIPT)作为一线筛查方法对比靶向NIPT与早孕期联合筛查的临床与经济影响:一项建模研究
本研究基于荷兰产科人群构建决策分析模型(175,000例妊娠),比较全基因组NIPT(GW-NIPT)作为一线筛查与靶向NIPT及早孕期联合筛查(FCT)的临床与经济影响。GW-NIPT诊断例数最多(545例)且每诊断成本最低(€152,785),所需侵入性检查最少(每诊断6例),但结果基于无质量调整生命年结局的模型,应视为相对比较而非成本效果判断。
要点
- GW-NIPT诊断例数545例,高于靶向NIPT的514例和FCT的452例。
- GW-NIPT每诊断成本€152,785,低于靶向NIPT的€159,852和FCT的€170,050。
- GW-NIPT与靶向NIPT每诊断需6例侵入性检查,低于FCT的13例。
核心结论
- 在所评估的策略中,一线GW-NIPT诊断产出最高且每诊断成本最低,以较低成本提高检出率并支持生殖自主权。
- 实施决策还应考虑当地定价、实验室能力和咨询资源。
- 未来将筛查结局与长期健康后果(如质量调整生命年或生命年)、医疗利用、成本和心理社会结局关联的研究将支持正式成本效果评价及产前筛查政策完善。
研究设计与样本
- 决策分析模型,队列为175,000例妊娠,反映荷兰产科人群。
- 所有策略筛查21三体(唐氏综合征)、18三体(爱德华兹综合征)和13三体(帕陶综合征);GW-NIPT额外考虑罕见常染色体三体及结构异常。
- 模型输入基于TRIDENT-2研究数据和历史FCT数据。
- 基础案例单位成本:超声扫描€166、FCT €191、NIPT €350。
- 进行敏感性分析以考虑模型参数不确定性和潜在国别差异。
主要发现
- GW-NIPT诊断例数545例,靶向NIPT 514例,FCT 452例。
- GW-NIPT每诊断成本€152,785,靶向NIPT €159,852,FCT €170,050。
- GW-NIPT和靶向NIPT每诊断需侵入性检查均为6例,FCT为13例,提示操作相关流产(医源性流产)风险更低。
- 敏感性分析表明检测接受度和单位成本强烈影响结果;当NIPT价格不超过€467时,GW-NIPT在每诊断成本方面仍最具优势。
临床怎么用
- 作者指出实施决策还应考虑当地定价、实验室能力和咨询资源。
- 原文未据此给出其他推荐。
局限性
- 使用决策分析模型,未纳入生活质量结局。
- 缺乏与明确成本效果阈值的比较。
- 结果应解释为相对临床和经济比较,而非成本效果判断。
- 未来需将筛查结局与长期健康后果、医疗利用、成本和心理社会结局关联的研究以支持正式成本效果评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the diagnostic yield of genome-wide non-invasive prenatal testing (GW-NIPT) is growing, but its comparative clinical and economic impact as a first-tier screening strategy for fetal chromosomal abnormalities remains unassessed. We compared GW-NIPT with targeted NIPT and first-trimester combined testing (FCT), in a Dutch setting where all pregnancies also undergo a routine second-trimester anomaly ultrasound scan (scan), to guide policymakers on optimal prenatal screening approaches. METHODS AND FINDINGS: We developed a decision-analytic model for a cohort of 175,000 pregnancies, reflecting the Dutch obstetric population. All strategies screened for common trisomies 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patau syndrome); GW-NIPT additionally considered rare autosomal trisomies and structural aberrations. Model inputs were based on the TRIDENT-2 study data and historical FCT data. Base-case unit costs were €166 (scan), €191 (FCT), and €350 (NIPT). Sensitivity analyses were conducted to account for uncertainties in model parameters and potential country-specific variations. Outcomes included total screening costs, number of fetal chromosomal abnormalities diagnosed, number of invasive procedures, and expected procedure-related euploid fetal losses. We summarized economic results as cost per diagnosed case and incremental cost per additional diagnosis across strategies. GW-NIPT yielded the highest number of diagnoses (545) versus targeted NIPT (514) and FCT (452), and the lowest cost per diagnosed case (€152,785), compared with targeted NIPT (€159,852) and FCT (€170,050). Invasive tests required per diagnosis were lower for GW-NIPT and targeted NIPT (both 6) than for FCT (13), implying a lower risk of procedure-related miscarriage (iatrogenic miscarriage). Sensitivity analyses indicated that test uptake and unit costs strongly influenced outcomes. GW-NIPT remained the most favorable in terms of cost per diagnosis for NIPT prices up to €467. Key limitations include the use of a decision-analytic model without quality-of-life outcomes and the lack of comparisons against explicit cost-effectiveness thresholds. Therefore, the results should be interpreted as relative clinical and economic comparisons rather than cost-effectiveness judgements. CONCLUSIONS: Among the strategies evaluated, first-tier GW-NIPT had the greatest diagnostic yield and the lowest cost per diagnosis, improving detection rates and supporting reproductive autonomy at lower costs. Implementation decisions should also consider local pricing, laboratory capacity, and counseling resources. Future research that links screening outcomes to long-term health consequences (e.g., quality-adjusted life years or life-years), healthcare utilization, costs, and psychosocial outcomes will enable formal cost-effectiveness evaluations and support further refinement of prenatal screening policy.
引用
- van Prooyen Schuurman L, de Koning HJ, Meier E, et al. Clinical and economic impact of genome-wide non-invasive prenatal testing (NIPT) as a first-tier screening method compared to targeted NIPT and first-trimester combined testing: A modeling study. PLoS Med. 2025. PMID: 41191637. doi:10.1371/journal.pmed.1004790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。